Loading…
Maker of medical devices and tissue products for cardiac and vascular surgery, including heart valves, stent grafts and preserved tissue.
Maker of medical devices and tissue products for cardiac and vascular surgery, including heart valves, stent grafts and preserved tissue.
Formerly CryoLife, it was renamed Artivion in 2022 after building out aortic products, notably the JOTEC stent grafts bought in 2017. Sales go to hospitals through direct sales and distributors, while preserved human tissue is processed from donated tissue and shipped to surgeons.
Moat: narrow (regulatory licence, brand, installed base). Niche cardiac/vascular device and tissue-processing brands built over decades, though smaller-scale than majors.
Headquarters: Atlanta, Georgia · Founded: 1997 · Employees: 1,800
Size Artivion (AORT) is a United States Health Care company (Medical Specialties) with a market value of $985M, the 2258th largest of 3,117 United States companies the cockpit tracks. Shares closed at $20.21 on 6 Nov 2026.
Performance Over six months the shares fell 20.5%, against -18.7% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 16.4% over the last twelve months (peer median +7.3%); the operating margin is 6.6% (peer median 11.9%).
Valuation It trades at 3,912.9× forward earnings against a peer median of 25.1× (most expensive of 16).
Capital Return on invested capital runs 6.4 points below its cost of capital (9.6% WACC).
Short interest Short interest is 7.7% of the free float (15 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $471M | $441M | $389M | $354M | $314M |
| Revenue growth | — | +14% | +10% | +13% | — |
| Gross profit | $288M | $270M | $233M | $214M | $187M |
| EBITDA | $55.8M | $56.6M | $51.7M | $37.9M | $37.4M |
| Net income | -$3.16M | $9.76M | -$13.3M | -$30.6M | -$19.1M |
| Free cash flow | -$9.16M | $839,000 | $11.0M | $11.1M | -$14.2M |
| Capital expenditure | $50.9M | $39.0M | $11.2M | $7.43M | $10.7M |
| Total debt | $408M | $259M | $362M | $359M | $357M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Artivion AORT | $985M | -20% | +16% | 7% | 3,912.9× | n/a |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| Edwards Lifesciences EW | $58.9B | +28% | +15% | 29% | 31.4× | 17.2% |
| Abbott Laboratories ABT | $190B | +30% | +10% | 14% | 18.8× | 5.6% |
| LeMaitre Vascular LMAT | $1.85B | -25% | +12% | 29% | 26.2× | 2.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AORT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.7% | -0.8% | 9th lowest of 21 |
| 6-month return | -20.5% | -18.7% | 7th lowest of 21 |
| Distance from 52-week high | -58.1% | -37.3% | 2nd lowest of 21 |
| Revenue growth (TTM) | +16.4% | +7.3% | 7th highest of 21 |
| Operating margin | 6.6% | 11.9% | 8th lowest of 21 |
| Forward P/E | 3,912.9× | 25.1× | most expensive of 16 |
| ROIC minus cost of capital | -6.4 pp | -0.9 pp | 5th lowest of 20 |
| EV / EBITDA | 23.6× | 15.3× | 4th most expensive of 9 |
| Net debt / EBITDA | 5.9× | -1.4× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Artivion AORT | United States | $985M | -20% | +16% | 7% | 3,912.9× | n/a | n/a |
| Castle Biosciences CSTL | United States | $993M | +64% | +3% | -9% | n/a | n/a | n/a |
| HOB Biotech 688656.SS | China | $972M | -22% | +6% | 7% | 188.9× | 40.1% | +12.4% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 62.1× | n/a | n/a |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 17.0× | 7.2% | +12.1% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Ceribell CBLL | United States | $1.03B | +32% | +31% | -70% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Integra LifeSciences IART | United States | $1.04B | -4% | +1% | 12% | 5.8× | 5.2% | +3.6% |
| Edan Instruments 300206.SZ | China | $1.05B | -19% | +14% | 17% | 18.8× | 7.7% | -2.9% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| L&C BIO 290650.KS | South Korea | $1.07B | -17% | +53% | 17% | 213.2× | n/a | n/a |